MWNA
MRSN

Marshall Wace North America’s Mersana Therapeutics MRSN Stock Holding History

Marshall Wace North America’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$558K Buy
+2,363
New +$690K ﹤0.01% 1091
2021
Q2 		– Sell
-8,616
Closed -$3.49M – 1647
2021
Q1 		$3.49M Buy
8,616
+5,268
+157% +$2.56M 0.01% 658
2020
Q4 		$2.23M Buy
+3,348
New +$1.86M 0.01% 728
2020
Q3 		– Sell
-25,127
Closed -$14.7M – 1381
2020
Q2 		$14.7M Buy
+25,127
New +$8.58M 0.1% 216

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Marshall Wace North America's MRSN Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Mersana Therapeutics (MRSN) in Q3 2021: 2,363 shares worth $558K. The stake represents ﹤0.01% of the portfolio and ranks #1091 among its holdings. This is a return to the name: Marshall Wace North America previously reported a position in MRSN as recently as Q1 2021.

Marshall Wace North America first reported a position in MRSN in Q2 2020 and has held it in 4 quarters since. The position peaked at $14.7M in Q2 2020. 109 funds tracked by Wall St. Rank hold MRSN as of Q3 2021.

  • Marshall Wace North America held 2,363 shares of Mersana Therapeutics worth $558K as of Q3 2021.
  • Mersana Therapeutics was a new Marshall Wace North America position in Q3 2021.
  • Mersana Therapeutics made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1091 holding.
  • Marshall Wace North America first reported a position in Mersana Therapeutics in Q2 2020 and has held it in 4 quarters since.
  • Marshall Wace North America's Mersana Therapeutics position peaked at $14.7M in Q2 2020.
  • 109 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.